Stocks / NASDAQ / Amryt Pharma plc

Amryt Pharma plc

Our Opinion

Amryt Pharma plc is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.

Supporting Evidence:

The company stated in the following press release that they use animals for product testing.

“Pre-clinical data collected from animal studies has shown that the HPAE-based gene therapy could increase of collagen VII levels in the skin. Because RDEB is caused by faulty collagen VII, a therapy that can restore its levels represents an attractive strategy for this unmet clinical need.” Read the following article

Company Description

Amryt Pharma plc (Amryt) is a United Kingdom-based commercial-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing treatments to help patients with rare and orphan diseases. The Company’s development candidate, Oleogel-S10 (Filsuvez) is a treatment for the cutaneous manifestations of junctional and dystrophic (JEB and DEB) epidermolysis bullosa. Amryt’s pre-clinical gene therapy platform, AP103, offers treatment for patients with DEB.

Company Website: